Skip to main content
Erschienen in: Der Nephrologe 6/2016

12.10.2016 | Nierentransplantation | Für Sie gelesen

Belatacept als „standard of care“ für die Nierentransplantation?

verfasst von: Prof. Dr. med. M. Wiesener

Erschienen in: Die Nephrologie | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Auszug

Vincenti F et al. (2016) Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 374(4):333–343 …
Literatur
1.
Zurück zum Zitat Durrbach A, Pestana JM, Florman S et al (2016) Long-term outcomes in belatacept-treated vs. cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study. Am J Transplant. doi:10.1111/ajt.13830 Durrbach A, Pestana JM, Florman S et al (2016) Long-term outcomes in belatacept-treated vs. cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study. Am J Transplant. doi:10.​1111/​ajt.​13830
2.
Zurück zum Zitat Espinosa J, Herr F, Tharp G et al (2016) CD57(+) CD4 T cells underlie belatacept-resistant allograft rejection. Am J Transplant 16:1102–1112CrossRefPubMed Espinosa J, Herr F, Tharp G et al (2016) CD57(+) CD4 T cells underlie belatacept-resistant allograft rejection. Am J Transplant 16:1102–1112CrossRefPubMed
3.
Zurück zum Zitat Gupta G, Regmi A, Kumar D et al (2015) Safe conversion from tacrolimus to belatacept in high immunologic risk kidney transplant recipients with allograft dysfunction. Am J Transplant 15:2726–2731CrossRefPubMed Gupta G, Regmi A, Kumar D et al (2015) Safe conversion from tacrolimus to belatacept in high immunologic risk kidney transplant recipients with allograft dysfunction. Am J Transplant 15:2726–2731CrossRefPubMed
4.
Zurück zum Zitat Lamb KE, Lodhi S, Meier-Kriesche HU (2011) Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 11:450–462CrossRefPubMed Lamb KE, Lodhi S, Meier-Kriesche HU (2011) Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 11:450–462CrossRefPubMed
5.
Zurück zum Zitat Le Meur Y, Aulagnon F, Bertrand D et al (2016) Effect of an early switch to belatacept among calcineurin inhibitor-intolerant graft recipients of kidneys from extended-criteria donors. Am J Transplant 16:2181–2186CrossRefPubMed Le Meur Y, Aulagnon F, Bertrand D et al (2016) Effect of an early switch to belatacept among calcineurin inhibitor-intolerant graft recipients of kidneys from extended-criteria donors. Am J Transplant 16:2181–2186CrossRefPubMed
7.
Zurück zum Zitat Pestana JO, Grinyo JM, Vanrenterghem Y et al (2012) Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 12:630–639CrossRefPubMed Pestana JO, Grinyo JM, Vanrenterghem Y et al (2012) Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 12:630–639CrossRefPubMed
8.
Zurück zum Zitat Rostaing L, Massari P, Garcia VD et al (2011) Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 6:430–439CrossRefPubMedPubMedCentral Rostaing L, Massari P, Garcia VD et al (2011) Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 6:430–439CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Rostaing L, Vincenti F, Grinyo J et al (2013) Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 13:2875–2883CrossRefPubMed Rostaing L, Vincenti F, Grinyo J et al (2013) Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 13:2875–2883CrossRefPubMed
10.
Zurück zum Zitat Vincenti F, Larsen CP, Alberu J et al (2012) Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 12:210–217CrossRefPubMed Vincenti F, Larsen CP, Alberu J et al (2012) Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 12:210–217CrossRefPubMed
Metadaten
Titel
Belatacept als „standard of care“ für die Nierentransplantation?
verfasst von
Prof. Dr. med. M. Wiesener
Publikationsdatum
12.10.2016
Verlag
Springer Medizin
Erschienen in
Die Nephrologie / Ausgabe 6/2016
Print ISSN: 2731-7463
Elektronische ISSN: 2731-7471
DOI
https://doi.org/10.1007/s11560-016-0096-8

Weitere Artikel der Ausgabe 6/2016

Der Nephrologe 6/2016 Zur Ausgabe

Update Nephrologie

Update Nephrologie

Mitteilungen der DGIM

Mitteilungen der DGIM

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.